Will Boyer is a partner in Gowling WLG’s Ottawa office and leader of the firm’s national IP Litigation & Strategy Practice Group. His practice focuses on pharma and biotech patent litigation. Will regularly represents brand pharmaceutical and biotechnology companies in high-stakes patent litigation, including in relation to EYLEA, XARELTO, HEMGENIX, STIVARGA, ADEMPAS, ICLUSIG, among others. Will has represented clients in these cases in trials, appeals and administrative judicial review proceedings before the Federal Court and Federal Court of Appeal. Will’s litigation expertise in this space includes patent-related Competition Act claims against brand pharmaceutical companies, where Will was counsel to the respondents in the first two Competition Act applications under the new expanded “abuse of dominance” provisions. In addition to Will’s pharmaceutical and biotechnology IP related expertise, Will has experience in enforcement and litigation regarding other types of patents as well as trademarks, copyright and trade secrets. Over the course of his career, Will has worked with a wide variety of clients, from large international companies to small and medium-sized companies across industries, including oil-and-gas, computer hardware and software, and sports equipment.
